Inputs: momentum, trendVelocity
Mixed signal: momentum 36/100, trend 62/100.
Prediction result · Ensemble engineUpdated 5:37 AM
RAREUltragenyx Pharmaceutical Inc. stock price outlook
$16.10-4.05% since prev closeNeutral
Ultragenyx Pharmaceutical Inc. (RARE) is trading at $16.1, down 4.05% since the previous close and +2.88% over the past week. Price sits below its 50-day average by 5.36%, with price momentum at 36/100 and trend velocity at 62/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is elevated (73/100) and the stock is 12% of the way up its 52-week range. The weighted factor score lands at 54/100 — a neutral signal. Research only, not investment advice.
Universal leanmarket
RARE
Ultragenyx Pharmaceutical Inc.
$16.10-4.05%
LEANNEUTRAL / wait for cleaner tape
WHY
- Ultragenyx Pharmaceutical Inc. (RARE) is trading at $16.1, down 4.05% since the previous close and +2.88% over the past week. Price sits below its 50-day average by 5.36%, with price momentum at 36/100 and trend velocity at 62/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is elevated (73/100) and the stock is 12% of the way up its 52-week range. The weighted factor score lands at 54/100 — a neutral signal. Research only, not investment advice.
- Bull input: Price near 52-week lows (12% of range) with trend turning up — mean-reversion candidate.
- Bear input: High volatility (73/100) without momentum support — wide path, more downside variance.
RISK
Signals are model output from public data, not personalized investment advice.
INVALIDATE
Invalidate when a clear catalyst or directional print replaces the mixed tape.
AI Signal
Neutral · Lean
live data
Full public-market mode: chart history, quote, and news inputs were available.
Chart feed
Cron market chart feed
Quote/history
Six-month public chart history loaded.
News feed
8 relevant headlines found.
Signal inputs
Technical factors and news sentiment evaluated across multiple signal inputs.
News Sentiment58/100
Price Momentum36/100
Trend Velocity62/100
Volatility Risk73/100
Historical Modeling: Visualized ranges are mathematically derived from historic volatility metrics, corporate filings, and option-implied volume profiles. They represent statistical points of interest for research purposes, not financial execution commands or advice.
Why It Matters
Signal Explanation
Ultragenyx Pharmaceutical Inc. (RARE) is trading at $16.1, down 4.05% since the previous close and +2.88% over the past week. Price sits below its 50-day average by 5.36%, with price momentum at 36/100 and trend velocity at 62/100. Sentiment across 8 recent headlines reads net constructive at 58/100. Volatility risk is elevated (73/100) and the stock is 12% of the way up its 52-week range. The weighted factor score lands at 54/100 — a neutral signal. Research only, not investment advice.
Analyst Engine · Specialist model ensemble
Trees disagree — no clear lean on RARE
Weighted factor score across 16 signal inputs evaluating 9 features: momentum, news, volume, volatility, range, sentiment divergence, trend structure, and oscillator. Consensus and weighting applied. Each specialist bot inspects a different slice of the feature set, casts a directional vote, and contributes a confidence weight to the final score.
Engine edgeLeanNeutral
Inputs: newsSentiment, dayChange
Sentiment 58/100 + price -4.0% are both mid-range.
Inputs: unusualVolume, dayChange
Volume read 18/100 with price drift -4.0% — no clear footprint.
Inputs: volatilityRisk, momentum
High volatility (73/100) without momentum support — wide path, more downside variance.
Inputs: pctOfRange, trendVelocity
Price near 52-week lows (12% of range) with trend turning up — mean-reversion candidate.
Inputs: newsSentiment, weekChange
Sentiment 58/100 vs week change 2.9% are in agreement — no divergence edge.
Inputs: vsSma50, momentum
Price within 5.4% of the 50d SMA — no clear structural read.
Inputs: momentum, trendVelocity
Oscillator at 49 — neutral zone.
Inputs: momentum, dayChange, vsSma50
Momentum 36/100 is not strong enough to confirm a breakout.
Inputs: newsSentiment, weekChange
News 58/100 and weekly change 2.9% do not create a clean follow-through read.
Inputs: unusualVolume, trendVelocity
Volume 18/100 is quiet while trend velocity stays firm — supply looks thin.
Inputs: volatilityRisk, pctOfRange, momentum
Volatility 73/100 does not give a clean compression read.
Inputs: pctOfRange, dayChange, weekChange
Range position 12% is too middle-of-the-road to matter.
Inputs: newsSentiment, momentum, weekChange
Sentiment 58/100 and momentum 36/100 are not aligned enough for a clean read.
Inputs: vsSma50, momentum, trendVelocity
50d SMA distance -5.4% is not decisive.
Inputs: momentum, trendVelocity, weekChange
Oscillator at 49 does not show a rebound edge.
Why the ensemble agrees
- Mixed signal: momentum 36/100, trend 62/100.
- Sentiment 58/100 + price -4.0% are both mid-range.
- Price within 5.4% of the 50d SMA — no clear structural read.
Counter-trees
- High volatility (73/100) without momentum support — wide path, more downside variance.
- Price near 52-week lows (12% of range) with trend turning up — mean-reversion candidate.
Bull Case
- Price near 52-week lows (12% of range) with trend turning up — mean-reversion candidate.
- Volume 18/100 is quiet while trend velocity stays firm — supply looks thin.
Bear Case
- High volatility (73/100) without momentum support — wide path, more downside variance.
Latest Market Headlines
Headline titles only, from the publisher named on each card. Each links to the original story.
Yahoo! Finance Canada62
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
10/31/2026, 12:51:41 AM
Stocktwits55
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
10/31/2026, 10:33:35 PM
Trefis67
What Needs To Be True To Buy USA Rare Earth Stock? - Trefis
10/29/2026, 12:23:46 AM
Reuters53
US FDA approves Inovio's treatment for rare throat disease; shares surge - Reuters
10/30/2026, 10:18:51 PM
CNBC58
Rare Stanley Druckenmiller post sends crypto-linked stock surging - CNBC
10/29/2026, 6:53:50 PM
Key stats
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Market cap
- $1.59B
- 52-week range
- $39.8899/$12.73
- Volume
- 2,334,345
- Avg volume
- 4,713,767
- Analyst 1-yr target
- $23.00
- Exchange
- NASDAQ-GS
Source: Nasdaq public quote data. Research only.
Earnings Intelligence
Next
Nov 3, 2026
Estimate
$-1.15
Actual
$-0.9
- • Last report Aug 4, 2026 (Jun 2026): EPS $-0.9 vs $-1.27 expected, +29.13% surprise.
- • Beat estimates in 1 of the last 4 quarters.
- • Next report expected Nov 3, 2026, consensus EPS $-1.15 (Zacks estimate via Nasdaq; the company may confirm a different date).
Risk Warnings
- • Signals are model output from public data, not personalized investment advice.
- • High volatility — position sizing and stops matter more here.
- • Confirm liquidity, spreads, and your own thesis before acting.
RARE questions
What is the MarketPicks AI signal for Ultragenyx Pharmaceutical Inc. stock (RARE)?
As of Nov 2, 12:37 AM ET, the ensemble reads neutral on RARE — no consensus — 13 of 16 bots holding, with 2 bull, 1 bear and 13 hold votes from 16 specialist bots. Research only, not investment advice.
What is the latest RARE price on MarketPicks?
RARE was $16.10 on the latest quote (Nov 2, 12:37 AM ET), -4.05% since the previous close. Quotes can be delayed.
What do the momentum and trend scores for RARE mean?
Scores run from 0 to 100, with 50 neutral. RARE shows momentum 36/100, trend velocity 62/100 and volatility risk 73/100, with news sentiment at 58/100.
Not financial advice. MarketPicks.ai is an impersonal research tool. AI output can be wrong. Investing involves risk of loss. Do your own research and consult a licensed professional. Full disclaimer.